Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma

European Journal of Haematology
Antonio PalumboM Boccadoro

Abstract

Thalidomide combined with conventional chemotherapies including oral melphalan shows significant anti-myeloma activity. To address this issue, feasibility and efficacy of a three drug combination consisting of intravenous (i.v.) melphalan, thalidomide and prednisone [M(i.v.)PT] was evaluated in advanced myeloma patients. Twenty-four advanced myeloma patients were treated with multiple cycles of a regimen consisting of low dose i.v. melphalan (20 mg/m2) at d 1, thalidomide at the dose of 50-100 mg/d given continuously and oral prednisone at the planned dose of 50 mg/d every other day. Intravenous melphalan was administered every fourth month. Median time from diagnosis was 40 months (range: 8-144 months). Fifteen patients (66%) had previously been treated with a combination of thalidomide and dexamethasone or with thalidomide alone. Overall, on an intent-to treat basis, 14 patients responded: three achieved near complete remission (nCR), seven achieved partial response (PR), four minimal response (MR). Six patients showed stable disease (SD) and four-disease progression. Interestingly, of five patients who had previously progressed while on thalidomide and prednisone, one reached nCR, two PR and one MR. After a median follow up ...Continue Reading

References

Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Aug 28, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DimopoulosN Anagnostopoulos
Nov 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vincent RajkumarThomas E Witzig
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donna WeberRaymond Alexanian
Apr 12, 2003·Leukemia·S V RajkumarT E Witzig
Aug 7, 2003·Journal of the National Cancer Institute·Joyce Baldwin
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K ZervasUNKNOWN Greek Myeloma Study Group
Jul 3, 2004·The Lancet Oncology·Benedetto BrunoMario Boccadoro

❮ Previous
Next ❯

Citations

Aug 26, 2009·Annals of Hematology·Youngil KohUNKNOWN Korean Multiple Myeloma Working Party
Apr 29, 2010·Current Hematologic Malignancy Reports·Jonathan KaufmanSagar Lonial
Aug 27, 2013·Current Hematologic Malignancy Reports·Jason P Meadows, Tomer M Mark
Mar 10, 2010·Medical Oncology·Tiffany Richards, Donna Weber
Nov 9, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A RomanoF Di Raimondo
Jan 18, 2011·Hematology·Sagar Lonial
Feb 5, 2008·Blood·Antonio PalumboJean-Luc Harousseau
Jan 8, 2010·Haematologica·Antonio PalumboUNKNOWN Italian Multiple Myeloma Network GIMEMA
Oct 10, 2006·Future Oncology·Jean-Luc Harousseau
Sep 13, 2014·Hematology/oncology Clinics of North America·Silvia Gentili, Sagar Lonial
Apr 25, 2007·Leukemia & Lymphoma·Federica CavalloAntonio Palumbo
Jul 9, 2008·Leukemia & Lymphoma·Donna E ReeceMichael J Kovacs
Jul 14, 2007·Expert Review of Anticancer Therapy·Patrizia FalcoAntonio Palumbo
Dec 18, 2013·Expert Review of Anticancer Therapy·Roberto CastelliMassimo Cugno
Dec 22, 2007·Expert Opinion on Investigational Drugs·Muralikrishnan SrikanthGareth J Morgan
Aug 24, 2007·Expert Opinion on Investigational Drugs·Pellegrino Musto, Fiorella D'Auria
Nov 13, 2014·Expert Opinion on Biological Therapy·Yvonne Mary PapamerkouriouJohn Kyrkos
Jul 16, 2008·Expert Opinion on Drug Metabolism & Toxicology·Iris Breitkreutz, Kenneth C Anderson
Sep 25, 2010·Cancer Treatment Reviews·Niels W C J van de DonkAntonio Palumbo
Oct 13, 2007·Clinical Lymphoma & Myeloma·Alfred Ian Lee, Nikhil C Munshi
Feb 3, 2009·British Journal of Haematology·Rakesh PopatJamie Cavenagh
Apr 4, 2015·Blood·Ajay K NookaSagar Lonial
Sep 22, 2006·Current Opinion in Oncology·Paul G RichardsonKenneth Anderson
Dec 17, 2009·The Cancer Journal·Sheeba K ThomasDonna M Weber
Jul 3, 2007·The Oncologist·Paul G RichardsonKenneth Anderson
Jun 11, 2020·Journal of Clinical Medicine·Roberto RiaAngelo Vacca
Mar 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sagar LonialPaul G Richardson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.